Two-Drug combo takes aim at deadly thyroid cancer

NCT ID NCT03085056

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This early-phase trial tests the safety and tolerability of combining two drugs—trametinib and paclitaxel—in people with anaplastic thyroid cancer, a rare and fast-growing cancer that is difficult to treat. The study aims to see how this drug pair affects tumor growth and shrinkage. Participants have cancer that has spread or cannot be removed surgically.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trametinib and paclitaxel
What this could lead to: If successful, this combination could offer a new treatment option for anaplastic thyroid cancer, a rare and aggressive disease with few effective therapies.
What could go wrong: This is a very early, small pilot study focused on safety and tolerability. The combination may not shrink tumors or improve survival, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid gland undifferentiated (anaplastic) carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC THYROID CANCER

Contacts and locations

Show contact details

Locations

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.